Literature DB >> 32672839

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.

Zhihua Ran1, Kaichun Wu2, Katsuyoshi Matsuoka3, Yoon Tae Jeen4, Shu Chen Wei5, Vineet Ahuja6, Minhu Chen7, Pin-Jin Hu8, Akira Andoh9, Hyo Jong Kim10, Suk-Kyun Yang11, Mamoru Watanabe12, Siew Chien Ng13, Toshifumi Hibi14, Ida Normiha Hilmi15, Yasuo Suzuki16, Dong Soo Han17, Wai Keung Leung18, Jose Sollano19, Choon Jin Ooi20, Jiaming Qian21.   

Abstract

Inflammatory bowel disease (IBD) has increased in incidence and prevalence in Asian countries since the end of the 20th century. Moreover, differences in the cause, phenotypes, and natural history of IBD between the East and West have been recognized. Therefore, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have established recommendations on medical management of IBD in Asia. Initially, the committee members drafted 40 recommendations, which were then assessed according to Grading of Recommendations Assessment, Development and Evaluation. Eight statements were rejected as this indicated that consensus had not been reached. The recommendations encompass pretreatment evaluation; medical management of active IBD; medical management of IBD in remission; management of IBD during the periconception period and pregnancy; surveillance strategies for colitis-associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Clostridium difficile; Crohn's disease; biologics; chronic ulcerative colitis; cytomegalovirus; inflammatory bowel disease; intestinal tuberculosis

Year:  2020        PMID: 32672839     DOI: 10.1111/jgh.15185

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

Review 1.  Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.

Authors:  Shailja C Shah; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2021-10-29       Impact factor: 22.682

2.  Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study.

Authors:  Zhao-Yang Chen; Yang-Hui Zhu; Ling-Yan Zhou; Wei-Qiao Shi; Zhou Qin; Bin Wu; Yu Yan; Yu-Wen Pei; Ning-Ning Chao; Rui Zhang; Mi-Ye Wang; Ze-Hao Su; Xiao-Jun Lu; Zhi-Yao He; Ting Xu
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

3.  Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic-A cost-effectiveness analysis.

Authors:  Jiaqi Yao; Ginenus Fekadu; Xinchan Jiang; Joyce H S You
Journal:  PLoS One       Date:  2022-04-07       Impact factor: 3.240

Review 4.  Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?

Authors:  Gustavo Drügg Hahn; Petra Anna Golovics; Panu Wetwittayakhlang; Alex Al Khoury; Talat Bessissow; Peter Laszlo Lakatos
Journal:  Biomedicines       Date:  2022-03-23

Review 5.  Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

Authors:  Sasha R Fehily; Aysha H Al-Ani; Jonathan Abdelmalak; Clarissa Rentch; Eva Zhang; Justin T Denholm; Douglas Johnson; Siew C Ng; Vishal Sharma; David T Rubin; Peter R Gibson; Britt Christensen
Journal:  Aliment Pharmacol Ther       Date:  2022-05-20       Impact factor: 9.524

6.  Presume Why Probiotics May Not Provide Protection in Inflammatory Bowel Disease through an Azoxymethane and Dextran Sodium Sulfate Murine Model.

Authors:  Ming-Luen Hu; Wei-Shiung Lian; Feng-Sheng Wang; Chao-Hui Yang; Wan-Ting Huang; Jing-Wen Yang; I-Ya Chen; Ming-Yu Yang
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

7.  Methotrexate showed efficacy both in Crohn's disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy.

Authors:  Mengyao Wang; Jingwen Zhao; Heran Wang; Changqing Zheng; Bing Chang; Lixuan Sang
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

8.  Fecal Calprotectin as a Surrogate Marker for Mucosal Healing After Initiating the Therapeutic Anti-Tubercular Trial.

Authors:  Satimai Aniwan
Journal:  Clin Endosc       Date:  2022-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.